(IN BRIEF) Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of novel antifungal and antibacterial treatments. The agreement provides an initial USD 29 million, with the potential … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Antibacterial Treatments, antifungal, BAL2062, Basilea, Biomedical Advanced Research and Development Authority (BARDA), David Veitch, fosmanogepix, partnership, sustainability, USA
(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for ZEVTERA® (ceftobiprole medocaril sodium for injection). The approval covers its use in adult patients with Staphylococcus aureus bloodstream infections (bacteremia), … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Adesh Kaul, Basilea, David Veitch, Dr. Marc Engelhardt, FDA, Pediatric Use, safety, Severe Bacterial Infections, Thomas Holland, Vance G. Fowler, Zevtera®
(IN BRIEF) Basilea Pharmaceutica Ltd (SIX: BSLN) has announced that its partner Knight Therapeutics Inc. (TSX: GUD) exceeded the sales threshold for the antifungal Cresemba (isavuconazole) in Latin America in 2023, triggering the first sales milestone payment for the region. … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged antifungal, Basilea, Cresemba®, David Veitch, Knight Therapeutics, Latin America, partnership, sustainability
(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company dedicated to addressing severe bacterial and fungal infections, has announced that its antifungal medication, Cresemba® (isavuconazole), has achieved robust sales performance in the Asia Pacific region and China through its licensing partner, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Antifungal Drug, Asia Pacific, Basilea, Cresemba®, David Veitch, partnership, Pfizer Inc.
BASEL, 11-Dec-2018 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba® (isavuconazole) by Astellas Pharma Inc. (“Astellas”) in the United States exceeded the threshold triggering a milestone payment to Basilea in the amount of … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged antifungal, aspergillosis, Astellas, Basilea, Cresemba®, Isavuconazole, mucormycosis
BASEL, 02-Oct-2017 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (CR Gosun) for Basilea’s antibiotic Zevtera®(ceftobiprole) in China, Hong … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?